Electrically stimulated 5‐hydroxytryptamine (5‐HT) release was monitored in slices of rat dorsal raphé nucleus (DRN) by fast cylic voltammetry. Pseudo‐single pulse stimulations (5 pulses at 100 Hz) were used to enable the effect of various receptor agonists to be seen without competition from endogenously released transmitter. The selective 5‐HT1A receptor agonist, (+)‐8‐OH‐DPAT (1.0 μm) decreased stimulated 5‐HT release to 31 ± 3% of controls. This decrease was inhibited by the 5‐HT1A receptor antagonists, (+)‐WAY‐100135 (1.0 μm) and WAY‐100635 (0.1 μm) but not by the 5‐HT1D/B antagonist, GR127935 (0.05 μm). The selective 5‐HT1B receptor agonist, CP‐93129 (0.3 μm) decreased stimulated 5‐HT release to 61 ± 4% of control. This effect was antagonized by the 5‐HT1B receptor antagonist, isamoltane (0.5 μm) but not by (+)‐WAY‐100135. The 5‐HT1D agonist, sumatriptan (0.5 μm) decreased stimulated 5‐HT release to 52 ± 2 % of controls. This decrease was blocked by GR‐127935 but not by WAY‐100635. These results suggest that 5‐HT release in the rat DRN is under the control of 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors.
1 September 1997 in British Journal of Anaesthesia
Tramadol is an atypical centrally acting analgesic agent with relatively weak opioid receptor affinity in comparison with its antinociceptive efficacy. Evidence suggests that block of monoamine uptake may contribute to its analgesic actions. Therefore, we have examined the actions of (+/-)-tramadol, (+)-tramadol, (-)-tramadol and O-desmethyltramadol (M1 metabolite) on electrically evoked 5-HT efflux and uptake in the dorsal raphe nucleus (DRN) brain slice, measured by fast cyclic voltammetry. Racemic tramadol and its (+)-enantiomer (both 5 mumol litre-1) significantly blocked DRN 5-HT uptake (both P < 0.05) and increased stimulated 5-HT efflux (P < 0.01 (+/-)-tramadol; P < 0.05 (+)-tramadol). The (-)-enantiomer and metabolite, O-desmethyltramadol, were inactive at the concentration tested (5 mumol litre-1). For both (+/-)-tramadol and the (+)-enantiomer, the action on 5-HT efflux preceded an effect on 5-HT uptake, suggesting that uptake block was not the cause of the increased 5-HT efflux and that tramadol might therefore have a direct 5-HT releasing action. This activity, at clinically relevant concentrations, may help to explain the antinociceptive efficacy of tramadol despite weak mu opioid receptor affinity and adds to evidence that tramadol exerts actions on central monoaminergic systems that may contribute to its analgesic effect.
1 December 2012 in Progress in Neuro-Psychopharmacology and Biological Psychiatry